2010-09-09

Dear Colleague,

Further to Customer Letters **2010-22**, *Pediatric Platelet Transfusions and the Discontinuation of the Production of CP2D Platelets LR in Saskatchewan* and **2010-29**, *Implementation of Fenwal Collection Sets/Automated Production Method at Canadian Blood Services- Saskatchewan UPDATE*, Canadian Blood Services will standardize production processes across all Centres and discontinue the production of CP2D Platelets LR in Saskatchewan on October 25th, 2010. After this time, single doses of CP2D Platelets LR for pediatric use will no longer be available. CPD Platelets, Pooled LR or Platelets Apheresis, LR will be the two products supplied by Canadian Blood Services.

In anticipation of this transition, Canadian Blood Services performed a study at our Development Laboratory (NetCAD) on the *in vitro* platelet quality in storage containers typically used by hospitals for pediatric transfusions. Canadian Blood Services has assessed the commonly used processes for obtaining platelet aliquots from Platelet Apheresis components and performed testing to determine platelet quality.

The following systems were included in these activities:
- gas permeable transfer packs which are licensed for storage up to 5 days
- non-gas permeable transfer packs used for short term storage under CSA standards.
- 60 mL syringes used for short term storage under CSA standards.

A summary of Canadian Blood Services “Validation Study – Project Report, *In vitro* Platelet Quality in Storage Containers Used for Pediatric Transfusions” along with “Pediatric Platelet Transfusions and the Discontinuation of the Production of CP2D Platelets LR in Saskatchewan - Questions & Answers” are posted on our transfusion medicine website (www.transfusionmedicine.ca). If you’d like to view the full Validation Study – Project Report of the study, please contact your local Hospital Liaison Specialist.

Each Hospital is advised to evaluate their current pediatric transfusion practices and determine if changes to internal policies will be required with the discontinuation of the CP2D platelet components as well as to assess validation requirements for their process.

This Customer Letter can also be viewed at www.blood.ca in the “Hospitals” section. If you have questions about this Customer Letter, please contact your local Hospital Liaison Specialist.

Sincerely,

Dana Devine, Ph.D.
Vice-President, Medical, Scientific and Research Affairs